Bronchopulmonary Dysplasia
Conditions
Brief summary
The clinical study with UMC119-01 is designed to investigate the safety in patients with bronchopulmonary dysplasia (BPD). This will be a dose escalation, open-label, single-center study in infants at high risk for BPD.
Detailed description
UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product which is intended for prevention of Bronchopulmonary dysplasia.
Interventions
BIOLOGICALHuman Umbilical Cord Derived-Mesenchymal Stem Cells
Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
Sponsors
Meridigen Biotech Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Days to 51 Days
Healthy volunteers
No
Inclusion criteria
Neonatal infants who fulfil all of the following criteria will be enrolled: 1. Subjects of postnatal age between 3 to 30 days. 2. Are male and female infants born at GA between 23 weeks to 29 weeks. The postmenstrual age of subject received UMC119-01 should be no more than PMA36 weeks. 3. Subjects with birth weight between 501g to 1249 g. 4. Have endotracheal tube in place as part of SoC for preterm infants with BPD at screening and on treatment visit (Day 0), and that they will have not been intubated for the purposes of this study. 5. A subject who is intubated and receiving mechanical ventilation with a fraction of inspired oxygen (FiO2) of 0.25 or greater at Screening. 6. A subject who has had either a deterioration or no change in the setting of mechanical ventilation within the 24 hours before trial enrollment. 7. Written informed consent has been provided by the subject's parents, legal guardians, or a legal representative, who agree to comply with all of the study procedures, including those in the long-term safety surveillance period.
Exclusion criteria
Neonatal infants who meet any of the following criteria will be excluded: 1. Have a major congenital abnormality, including neurological (including anencephaly and similar malformations), hepatic, renal, cardiovascular abnormality (except for patent ductus arteriosus, PDA). 2. Have a known genetic syndrome. 3. Have a condition that makes them ineligible for participation in this study, as determined by the investigator. 4. Have C-reactive protein (CRP) \>30 mg/L; or any infections including pneumonia, sepsis, or shock. 5. Have pre-existing severe intraventricular hemorrhage (IVH) (grade ≥3). 6. Have active pulmonary hemorrhage or air leak syndrome. 7. Have abnormal hepatic (AST, ALT \>150 U/L or direct bilirubin \>2 mg/dL or total bilirubin \>15 mg/dL) or renal function (serum creatinine \>1 mg/dL or oliguria). 8. Are known to be infected with HIV or CMV. 9. Are expected to have surgery within 24 hours prior to and/or after UMC119 01 instillation. 10. Are expected to receive any other intratracheal treatments, including surfactant within 72 hours prior to and/or after UMC119 01 instillation. 11. Are currently participating in any other interventional clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence and frequency of adverse events related to administration of UMC119-01. | 3 months from the day of administration | • The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs), including their relationship to the administration of UMC119 01. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of the oxygen saturation. | 3 months from the day of administration | Changes from baseline of the oxygen saturation. |
| Changes of chest x-ray findings in participants before and after administration. | 3 months from the day of administration | Changes from baseline to 3 months of chest x-ray findings in participants before and after administration. |
| Changes of inflammatory markers (pg/ml) before and after administration. | 3 days and 7 days after administration | Changes from baseline of inflammatory markers (pg/ml) . |
| The percentage of subjects who died from any cause during the study. | 3 months from the day of administration | The percentage of subjects who died from any cause during the study. |
| The number of days of intubation, or where ventilator or oxygen therapy. | 3 months from the day of administration | The number of days of intubation, or where ventilator or oxygen therapy. |
| Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA). | 36 weeks postmenstrual age (PMA) | Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA). |
| Comparison of the incidence and severity of preterm children's complications in participants before and after administration. | 3 months from the day of administration | Comparison of the incidence and severity of preterm children's complications in participants before and after administration. |
Countries
Taiwan
Contacts
Primary ContactClaire Liao, MS
Backup ContactJoseph Chen
Outcome results
None listed